NEW YORK (TheStreet) -- Shares of BaxterInt'l (BAX) - Get Report were higher in late-afternoon trading on Monday ahead of the company's 2016 third quarter results, due out before tomorrow's opening bell.

Wall Street is forecasting that earnings and revenue will increase year-over-year.

Analysts surveyed by FactSet are projecting that the healthcare, renal and hospital products company will report earnings of 45 cents per share on revenue of $2.55 billion.

During the same quarter last year, the Deerfield, IL-based company earned 41 cents per diluted share on revenue of $2.49 billion.

TST Recommends

Separately, TheStreet Ratings Team has a "Buy" rating with a score of A- on the stock.

The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. 

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: BAX

Image placeholder title